AU - Mahmoodi Nesheli, Hassan AU - Hadizadeh, Amereh AU - Bijani, Ali TI - Evaluation of inhibitor antibodies in haemophilia A population PT - JOURNAL ARTICLE TA - babol-caspjim JN - babol-caspjim VO - 4 VI - 3 IP - 3 4099 - http://caspjim.com/article-1-212-en.html 4100 - http://caspjim.com/article-1-212-en.pdf SO - babol-caspjim 3 AB  - Background: Inhibitory antibody to exogenous Factor VIII (FVIII) is a major complication of hemophilia treatment. This study was conducted to determine the prevalence of inhibitor antibody directed against FVIII.Methods: From May 2010 to May 2011, 52 patients with severe hemophilia A admitted in Amirkola Children’s Hospital were evaluated. Those who had abnormal mixing study, antibody against FVIII were measured. Data were collected and analyzed. Results: The age range of the patients was 4-60 years. The inhibitor antibody was seen in 9 (17.3%) patients. The mean age of patients with inhibitor at the time of diagnosis was 10.22 years (ranged 4-31 years). Old patients had more hemarthrosis than young patients. The mean level of inhibitor antibody was 8.47 Bethesda (ranged 2.3-29). Six patients had inhibitor antibody level ?5 Bethesda unit and three patients had inhibitor antibody level CP - IRAN IN - LG - eng PB - babol-caspjim PG - 727 PT - Original Article YR - 2013